Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Suzanne George, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Novotny JP, George S. Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options? Curr Treat Options Oncol. 2021 09 15; 22(11):99. PMID: 34524549.
    Citations:    Fields:    
  2. Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 Sep 09. PMID: 34503977.
    Citations:    Fields:    
  3. Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Somaiah N, Meade J, Reichert V, Shi K, Sherman ML, Ruiz-Soto R, von Mehren M, Blay JY. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist. 2021 Nov; 26(11):e2053-e2060. PMID: 34313371.
    Citations:    Fields:    
  4. George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku F. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244. PMID: 34391056.
    Citations:    Fields:    
  5. Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 Oct 01; 39(28):3128-3139. PMID: 34343033.
    Citations:    Fields:    
  6. Bauer S, George S, von Mehren M, Heinrich MC. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. Front Oncol. 2021; 11:672500. PMID: 34322383.
    Citations:    
  7. Jagannathan JP, Steiner A, Bay C, Eisenhauer E, Muto MG, George S, Fennessy FM. Differentiating leiomyosarcoma from leiomyoma: in support of an MR imaging predictive scoring system. Abdom Radiol (NY). 2021 10; 46(10):4927-4935. PMID: 34075468.
    Citations:    Fields:    Translation:Humans
  8. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 Aug 15; 127(16):2934-2942. PMID: 33910263.
    Citations:    Fields:    
  9. von Mehren M, Heinrich MC, Shi H, Iannazzo S, Mankoski R, Dimitrijevic S, Hoehn G, Chiroli S, George S. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. BMC Cancer. 2021 Mar 19; 21(1):291. PMID: 33740926.
    Citations:    Fields:    Translation:Humans
  10. Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M, Hattori C, Abe M, Hasegawa J, Iguchi T, Karibe T, Nakada T, Inaki K, Kamei R, Abe Y, Nomura T, Andersen JL, Santagata S, Hemming ML, George S, Doi T, Ochiai A, Demetri GD, Agatsuma T. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun; 11(6):1508-1523. PMID: 33579785.
    Citations: 2     Fields:    
  11. Kim ES, Uldrick TS, Schenkel C, Bruinooge SS, Harvey RD, Magnuson A, Spira A, Wade JL, Stewart MD, Vega DM, Beaver JA, Denicoff AM, Ison G, Ivy SP, George S, Perez RP, Spears PA, Tap WD, Schilsky RL. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021 May 01; 27(9):2394-2399. PMID: 33563632.
    Citations:    Fields:    
  12. George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649. PMID: 33453089.
    Citations: 1     Fields:    Translation:Humans
  13. Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schöffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142. PMID: 33465704.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  14. von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Meyer C, Pappo AS, Parkes AM, Paz IB, Petersen IA, Poppe M, Riedel RF, Rubin B, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Bergman MA, George GV. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw. 2020 12 02; 18(12):1604-1612. PMID: 33285515.
    Citations: 11     Fields:    
  15. Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303. PMID: 32804590.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  16. Sullivan MW, Gockley A, Lo YC, Sholl LM, George S, Feltmate C. Superior Vena Cava Syndrome associated with recurrent uterine adenosarcoma. Gynecol Oncol Rep. 2020 Aug; 33:100613. PMID: 32760777.
    Citations:    
  17. Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, Cassier PA, Mir O, Eskens F, Tap WD, Rutkowski P, Chawla SP, Trent J, Tugnait M, Evans EK, Lauz T, Zhou T, Roche M, Wolf BB, Bauer S, George S. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 07; 21(7):935-946. PMID: 32615108.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  18. Serrano C, George S. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Clin Cancer Res. 2020 10 01; 26(19):5078-5085. PMID: 32601076.
    Citations: 8     Fields:    
  19. Hemming ML, Fan C, Raut CP, Demetri GD, Armstrong SA, Sicinska E, George S. Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Mol Cancer Res. 2020 09; 18(9):1302-1314. PMID: 32518213.
    Citations: 4     Fields:    Translation:Humans
  20. Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 07; 21(7):923-934. PMID: 32511981.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  21. Gelderblom H, Jones RL, George S, Valverde Morales C, Benson C, Renouf DJ, Doi T, Le Cesne A, Leahy M, Hertle S, Aimone P, Brandt U, Sch?ffski P. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. Br J Cancer. 2020 04; 122(8):1158-1165. PMID: 32147671.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  22. Serrano C, Vivancos A, López-Pousa A, Matito J, Mancuso FM, Valverde C, Quiroga S, Landolfi S, Castro S, Dopazo C, Sebio A, Virgili AC, Menso MM, Martín-Broto J, Sansó M, García-Valverde A, Rosell J, Fletcher JA, George S, Carles J, Arribas J. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer. 2020 Feb 05; 20(1):99. PMID: 32024476.
    Citations: 5     Fields:    Translation:Humans
  23. Cote GM, Choy E, Chen T, Marino-Enriquez A, Morgan J, Merriam P, Thornton K, Wagner AJ, Nathenson MJ, Demetri G, George S. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32. PMID: 31896519.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  24. George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012 Dec; 23(12):3180-3187. PMID: 32018827.
    Citations:    
  25. von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele AD. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 04 15; 26(8):1837-1845. PMID: 31792037.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  26. Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schöffski P, Mehren MV, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol. 2020 Jan; 16(1):4251-4264. PMID: 31755321.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  27. Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293. PMID: 31471313.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  28. Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy". Sarcoma. 2019; 2019:7608743. PMID: 31534435.
    Citations: 1     
  29. Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Jul; 121(3):281. PMID: 31123346.
    Citations: 1     Fields:    
  30. Amin-Mansour A, George S, Sioletic S, Carter SL, Rosenberg M, Taylor-Weiner A, Stewart C, Chevalier A, Seepo S, Tracy A, Getz G, Hornick JL, Nucci MR, Quade B, Demetri GD, Raut CP, Garraway LA, Van Allen EM, Wagner AJ. Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clin Cancer Res. 2019 08 15; 25(16):5135-5142. PMID: 31164371.
    Citations: 6     Fields:    Translation:Humans
  31. Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 03; 120(6):612-620. PMID: 30792533.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  32. Doyle LA, Nowak JA, Nathenson MJ, Thornton K, Wagner AJ, Johnson JM, Albrayak A, George S, Sholl LM. Characteristics of mismatch repair deficiency in sarcomas. Mod Pathol. 2019 07; 32(7):977-987. PMID: 30765880.
    Citations: 9     Fields:    Translation:HumansCells
  33. Hemming ML, Klega KS, Rhoades J, Ha G, Acker KE, Andersen JL, Thai E, Nag A, Thorner AR, Raut CP, George S, Crompton BD. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. JCO Precis Oncol. 2019; 2019. PMID: 30793095.
    Citations: 15     
  34. Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma. 2018; 2018:2068517. PMID: 30473623.
    Citations: 3     
  35. George S, Wagner AJ. Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. JAMA Oncol. 2018 09 01; 4(9):1169-1170. PMID: 29879275.
    Citations: 2     Fields:    Translation:Humans
  36. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Keedy V, Kim E, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, Morris ZS, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap WD, Wayne JD, Bergman MA, Scavone JL. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 05; 16(5):536-563. PMID: 29752328.
    Citations: 120     Fields:    Translation:Humans
  37. Mariño-Enriquez A, Lauria A, Przybyl J, Ng TL, Kowalewska M, Debiec-Rychter M, Ganesan R, Sumathi V, George S, McCluggage WG, Nucci MR, Lee CH, Fletcher JA. BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. Am J Surg Pathol. 2018 03; 42(3):335-341. PMID: 29200103.
    Citations: 17     Fields:    Translation:HumansCells
  38. George S, Serrano C, Hensley ML, Ray-Coquard I. Soft Tissue and Uterine Leiomyosarcoma. J Clin Oncol. 2018 01 10; 36(2):144-150. PMID: 29220301.
    Citations: 22     Fields:    Translation:Humans
  39. Serrano C, George S, Valverde C, Olivares D, García-Valverde A, Suárez C, Morales-Barrera R, Carles J. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Target Oncol. 2017 06; 12(3):277-288. PMID: 28478525.
    Citations: 10     Fields:    Translation:HumansAnimals
  40. Pretz JL, Barysauskas CM, George S, Hornick JL, Raut CP, Chen YE, Marcus KJ, Choy E, Hornicek F, Ready JE, DeLaney TF, Baldini EH. Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. Oncologist. 2017 10; 22(10):1265-1270. PMID: 28550026.
    Citations: 10     Fields:    Translation:Humans
  41. George S. Evolving Treatment of Soft Tissue Sarcoma. J Natl Compr Canc Netw. 2017 05; 15(5S):733-736. PMID: 28515258.
    Citations: 1     Fields:    Translation:Humans
  42. Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, Cunningham A, Rodig SJ, Hodi FS, Morgan JA, Merriam P, Wagner AJ, Shapiro GI, George S. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290. PMID: 28440953.
    Citations: 49     Fields:    Translation:HumansCTClinical Trials
  43. Hemming ML, Wagner AJ, Nucci MR, Chiang S, Wang L, Hensley ML, George S. YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecol Oncol. 2017 06; 145(3):531-535. PMID: 28390819.
    Citations: 6     Fields:    Translation:Humans
  44. George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204. PMID: 28228279.
    Citations: 138     Fields:    Translation:HumansCellsCTClinical Trials
  45. Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol. 2017 Feb 10; 35(5):523-528. PMID: 28029307.
    Citations: 20     Fields:    Translation:Humans
  46. Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, Trent JC, von Mehren M, Wright JA, Schiffman JD, Raygada M, Pacak K, Meltzer PS, Miettinen MM, Stratakis C, Janeway KA, Helman LJ. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016 Jul 01; 2(7):922-8. PMID: 27011036.
    Citations: 96     Fields:    Translation:HumansCells
  47. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 06; 14(6):758-86. PMID: 27283169.
    Citations: 89     Fields:    Translation:Humans
  48. Braschi-Amirfarzan M, Keraliya AR, Krajewski KM, Tirumani SH, Shinagare AB, Hornick JL, Baldini EH, George S, Ramaiya NH, Jagannathan JP. Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists. Radiographics. 2016 May-Jun; 36(3):767-82. PMID: 27163593.
    Citations: 22     Fields:    Translation:Humans
  49. Shinagare AB, Barysauskas CM, Braschi-Amirfarzan M, O'Neill AC, Catalano PJ, George S, Ramaiya NH. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clin Imaging. 2016 Sep-Oct; 40(5):880-4. PMID: 27179958.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  50. Strickland KC, Nucci MR, Esselen KM, Muto MG, Chopra S, George S, Howitt BE. Solitary Fibrous Tumor of the Uterus Presenting With Lung Metastases: A Case Report. Int J Gynecol Pathol. 2016 Jan; 35(1):25-9. PMID: 26107564.
    Citations: 3     Fields:    Translation:Humans
  51. Blanke CD, Rankin C, Corless C, Eary JF, Mulder K, Okuno SH, George S, Heinrich M. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2015 Dec; 20(12):1353-4. PMID: 26576593.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  52. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL. Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015 Nov; 13(11):1321-31. PMID: 26553763.
    Citations: 15     Fields:    Translation:Humans
  53. Oduyebo T, Hinchcliff E, Meserve EE, Seidman MA, Quade BJ, Rauh-Hain JA, George S, Nucci MR, del Carmen MG, Muto MG. Risk Factors for Occult Uterine Sarcoma Among Women Undergoing Minimally Invasive Gynecologic Surgery. J Minim Invasive Gynecol. 2016 Jan; 23(1):34-9. PMID: 26253281.
    Citations: 2     Fields:    Translation:Humans
  54. Tanguturi SK, George S, Marcus KJ, Demetri GD, Baldini EH. Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment. Sarcoma. 2015; 2015:591698. PMID: 26199562.
    Citations: 2     
  55. Tirumani SH, Wagner AJ, Tirumani H, Shinagare AB, Jagannathan JP, Hornick JL, George S, Ramaiya NH. Is the nonlipomatous component of dedifferentiated liposarcoma always soft tissue on CT? Analysis of CT densities and correlation with rate of growth in 60 patients. Abdom Imaging. 2015 Jun; 40(5):1248-54. PMID: 25287680.
    Citations: 2     Fields:    Translation:Humans
  56. Goldberg JM, Fisher DE, Demetri GD, Neuberg D, Allsop SA, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, Morgan JA, Wagner AJ, Freeman GJ, Ritz J, Lezcano C, Mihm M, Canning C, Hodi FS, Dranoff G. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86. PMID: 25805798.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  57. Hameed M, Corless C, George S, Hornick JL, Kakar S, Lazar AJ, Tang L. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors. Arch Pathol Lab Med. 2015 Oct; 139(10):1271-5. PMID: 25729899.
    Citations:    Fields:    Translation:Humans
  58. Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30. PMID: 25536954.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  59. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813. PMID: 25374341.
    Citations: 48     Fields:    Translation:HumansCTClinical Trials
  60. Rauh-Hain JA, Hinchcliff EM, Oduyebo T, Worley MJ, Andrade CA, Schorge JO, George S, Muto MG, del Carmen MG. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma. Int J Gynecol Cancer. 2014 Oct; 24(8):1434-40. PMID: 25248114.
    Citations: 2     Fields:    Translation:Humans
  61. Shinagare AB, Ip IK, Lacson R, Ramaiya NH, George S, Khorasani R. Gastrointestinal stromal tumor: optimizing the use of cross-sectional chest imaging during follow-up. Radiology. 2015 Feb; 274(2):395-404. PMID: 25203129.
    Citations: 3     Fields:    Translation:Humans
  62. George S, Muto MG. Reply to in-bag morcellation for presumed myoma retrieval at laparoscopy. Cancer. 2014 Dec 15; 120(24):4005. PMID: 25102828.
    Citations:    Fields:    Translation:Humans
  63. Tirumani SH, Deaver P, Shinagare AB, Tirumani H, Hornick JL, George S, Ramaiya NH. Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients. J Gynecol Oncol. 2014 Oct; 25(4):306-12. PMID: 25142630.
    Citations: 14     Fields:    Translation:Humans
  64. George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014 Oct 15; 120(20):3154-8. PMID: 24923260.
    Citations: 28     Fields:    Translation:Humans
  65. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Gastrointestinal stromal tumors, version 2.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):853-62. PMID: 24925196.
    Citations: 40     Fields:    Translation:Humans
  66. Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014 Jun; 19(6):669-80. PMID: 24821824.
    Citations: 23     Fields:    Translation:Humans
  67. Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol. 2014 May; 6(3):115-27. PMID: 24790651.
    Citations: 24     
  68. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg. 2014 May; 259(5):973-8. PMID: 24477160.
    Citations: 29     Fields:    Translation:Humans
  69. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU, Delaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):473-83. PMID: 24717567.
    Citations: 34     Fields:    Translation:Humans
  70. Serrano C, Nucci MR, Tirumani SH, Raut CP, George S. Hormone dependency in metastatic low-grade leiomyosarcoma following uterine smooth muscle tumour of uncertain malignant potential. BMJ Case Rep. 2014 Mar 27; 2014. PMID: 24675802.
    Citations: 1     Fields:    Translation:Humans
  71. Saboo SS, Ramaiya N, Jacene H, Rainville I, Diller L, Hornick JL, George S. Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9. PMID: 22581272.
    Citations: 1     Fields:    Translation:Humans
  72. Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer. 2014 Mar; 50(5):981-6. PMID: 24388774.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  73. Coccia PF, Pappo AS, Altman J, Bhatia S, Borinstein SC, Flynn J, Frazier AL, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack B, Shead DA, Sundar H. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw. 2014 Jan; 12(1):21-32; quiz 32. PMID: 24453290.
    Citations: 28     Fields:    Translation:Humans
  74. Oduyebo T, Rauh-Hain AJ, Meserve EE, Seidman MA, Hinchcliff E, George S, Quade B, Nucci MR, Del Carmen MG, Muto MG. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol. 2014 Feb; 132(2):360-5. PMID: 24296345.
    Citations: 26     Fields:    Translation:Humans
  75. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43. PMID: 24222211.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  76. Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 01; 19(21):6020-9. PMID: 24045182.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  77. Serrano C, George S. Leiomyosarcoma. Hematol Oncol Clin North Am. 2013 Oct; 27(5):957-74. PMID: 24093170.
    Citations: 29     Fields:    Translation:Humans
  78. Rauh-Hain JA, Oduyebo T, Diver EJ, Guseh SH, George S, Muto MG, del Carmen MG. Uterine leiomyosarcoma: an updated series. Int J Gynecol Cancer. 2013 Jul; 23(6):1036-43. PMID: 23714705.
    Citations: 5     Fields:    Translation:Humans
  79. Iasonos A, Keung EZ, Zivanovic O, Mancari R, Peiretti M, Nucci M, George S, Colombo N, Carinelli S, Hensley ML, Raut CP. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer. 2013 May 15; 119(10):1816-22. PMID: 23456762.
    Citations: 12     Fields:    Translation:Humans
  80. Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res. 2013 Feb 15; 19(4):909-19. PMID: 23403628.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  81. McBride SM, Raut CP, Lapidus M, Devlin PM, Marcus KJ, Bertagnolli M, George S, Baldini EH. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol. 2013 Jul; 20(7):2140-7. PMID: 23392853.
    Citations: 15     Fields:    Translation:Humans
  82. Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013 Apr 15; 119(8):1555-61. PMID: 23335221.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  83. Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, Treister N. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol. 2013 Apr; 49(4):293-8. PMID: 23312237.
    Citations: 23     Fields:    Translation:Humans
  84. Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, Marcus KJ, Bertagnolli MM, Devlin PM, George S, Abraham J, Ferrone ML, Ready JE, Raut CP. Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol. 2013 May; 20(5):1494-9. PMID: 23242820.
    Citations: 24     Fields:    Translation:Humans
  85. Ravegnini G, Mariño-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, Nucci MR, George S, Angelini S, Raut CP, Fletcher JA. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol. 2013 May; 26(5):743-9. PMID: 23222489.
    Citations: 30     Fields:    Translation:Humans
  86. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol. 2013 Feb; 26(2):289-94. PMID: 22955521.
    Citations: 39     Fields:    Translation:Humans
  87. Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Pappo AS, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2012 Sep; 10(9):1112-50. PMID: 22956810.
    Citations: 74     Fields:    Translation:Humans
  88. Morgan EA, Kozono DE, Wang Q, Mery CM, Butrynski JE, Baldini EH, George S, Nascimento AF, Raut CP. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol. 2012 Nov; 19(12):3801-8. PMID: 22890593.
    Citations: 17     Fields:    Translation:Humans
  89. George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012 Dec; 23(12):3180-3187. PMID: 22858558.
    Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
  90. von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz B, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Aug; 10(8):951-60. PMID: 22878820.
    Citations: 50     Fields:    Translation:Humans
  91. de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, Wang Q, Demetri G, George S, Humphreys BD. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens. 2012 Oct; 25(10):1118-23. PMID: 22785409.
    Citations: 13     Fields:    Translation:Humans
  92. Shah SH, Jagannathan JP, Krajewski K, O'Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol. 2012 Jul; 199(1):213-23. PMID: 22733915.
    Citations: 19     Fields:    Translation:Humans
  93. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7. PMID: 22614970.
    Citations: 86     Fields:    Translation:HumansCTClinical Trials
  94. Jagannathan JP, Ramaiya NH, Shinagare AB, Hornick JL, George S. Intracranial metastasis from pediatric GI stromal tumor. J Clin Oncol. 2012 Apr 01; 30(10):e122-5. PMID: 22370323.
    Citations: 5     Fields:    Translation:Humans
  95. de Oliveira MA, Martins E Martins F, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol. 2011 Oct; 47(10):998-1003. PMID: 21890398.
    Citations: 25     Fields:    Translation:Humans
  96. Kollmannsberger C, Bjarnason G, Burnett P, Creel P, Davis M, Dawson N, Feldman D, George S, Hershman J, Lechner T, Potter A, Raymond E, Treister N, Wood L, Wu S, Bukowski R. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist. 2011; 16(5):543-53. PMID: 21490127.
    Citations: 23     Fields:    Translation:Humans
  97. Wang WL, Conley A, Reynoso D, Nolden L, Lazar AJ, George S, Trent JC. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011 Jan; 67 Suppl 1:S15-24. PMID: 21181476.
    Citations: 22     Fields:    Translation:Humans
  98. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011 Feb 15; 17(4):871-9. PMID: 21177764.
    Citations: 79     Fields:    Translation:HumansCTClinical Trials
  99. George S, Trent JC. The role of imatinib plasma level testing in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011 Jan; 67 Suppl 1:S45-50. PMID: 21140148.
    Citations: 4     Fields:    Translation:Humans
  100. Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):361-7. PMID: 20951504.
    Citations: 21     Fields:    Translation:Humans
  101. Marrari A, Trent JC, George S. Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr Opin Oncol. 2010 Jul; 22(4):336-41. PMID: 20489620.
    Citations: 4     Fields:    Translation:Humans
  102. Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW. Bone cancer. J Natl Compr Canc Netw. 2010 Jun; 8(6):688-712. PMID: 20581300.
    Citations: 11     Fields:    Translation:Humans
  103. Quek R, George S. Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics. 2010 Feb 04; 4:19-31. PMID: 20161982.
    Citations: 7     
  104. Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb; 17(2):407-15. PMID: 19898902.
    Citations: 28     Fields:    Translation:Humans
  105. Theman TA, Hartzell TL, Sinha I, Polson K, Morgan J, Demetri GD, Orgill DP, George S. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol. 2009 Nov 20; 27(33):e198-200. PMID: 19805684.
    Citations: 9     Fields:    Translation:Humans
  106. Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 2009 Sep 15; 115(18):4055-63. PMID: 19526590.
    Citations: 20     Fields:    Translation:Humans
  107. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9. PMID: 19737946.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  108. Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, Morgan JA, Muto MG, Fletcher CD, George S. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009 Nov; 45(16):2818-24. PMID: 19647426.
    Citations: 13     Fields:    Translation:Humans
  109. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3154-60. PMID: 19451429.
    Citations: 104     Fields:    Translation:HumansCTClinical Trials
  110. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009 Jul; 45(11):1959-68. PMID: 19282169.
    Citations: 126     Fields:    Translation:HumansCTClinical Trials
  111. Quek R, George S. Gastrointestinal stromal tumor: a clinical overview. Hematol Oncol Clin North Am. 2009 Feb; 23(1):69-78, viii. PMID: 19248971.
    Citations: 17     Fields:    Translation:Humans
  112. Quek R, Morgan JA, George S, Butrynski JE, Polson K, Meyer F, Demetri GD, Block SD. Small molecule tyrosine kinase inhibitor and depression. J Clin Oncol. 2009 Jan 10; 27(2):312-3. PMID: 19064960.
    Citations: 4     Fields:    Translation:Humans
  113. Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res. 2008 Sep 01; 14(17):5626-34. PMID: 18765557.
    Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
  114. Bertagnolli MM, Morgan JA, Fletcher CD, Raut CP, Dileo P, Gill RR, Demetri GD, George S. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008 Nov; 44(16):2404-10. PMID: 18706807.
    Citations: 19     Fields:    Translation:Humans
  115. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008 Feb 20; 100(4):282-4. PMID: 18270341.
    Citations: 53     Fields:    Translation:HumansCells
  116. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15; 370(9604):2011-9. PMID: 18083403.
    Citations: 291     Fields:    Translation:HumansAnimals
  117. Keohan ML, Morgan JA, D'Adamo DA, Harmon DC, Butrynski JE, Wagner AJ, Akhurst T, Schwartz GK, Van den Abeele AD, Quigley MT, Flanagan D, Bhuchar G, Demetri GD, Maki RG, George S. A phase II study of continuous dosing sunitinib in patients with non-GIST soft tissue sarcoma: early results [abstract]. Connective Tissue Oncology Society. 2007; 881.
  118. Dileo P, George S. Potential Benefit of Gencitabine and Vinorelbine Combination Chemotherapy for Patients With Advanced Soft Tissue Sarcomas. The American Journal of Hematology/Oncology. 2007; 6:647-649.
  119. Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP. Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol. 2007 Dec; 14(12):3534-41. PMID: 17896156.
    Citations: 27     Fields:    Translation:Humans
  120. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405. PMID: 17875769.
    Citations: 44     Fields:    Translation:HumansCells
  121. George, Suzanne; Demetri, George D. Dermatofibrosarcoma protuberans case report: when drug therapy can obviate the need for surgery. Community Oncology. 2007; 4(7):462-463.
  122. George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep. 2007 Jul; 9(4):323-7. PMID: 17588358.
    Citations: 12     Fields:    Translation:Humans
  123. C. P. Raut, J. A. Morgan, M. T. Quigley, S. George, A. J. Wagner, G. D. Demetri, M. M. Bertagnolli. Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors [abstract]. Proceedings of the American Society of Clinical Oncology. 2007; 10044.
  124. S. George, J. Y. Blay, P. G. Casali, A. Le Cesne, J. A. Morgan, J. Pokela, M. T. Quigley, V. Tassell, C. M. Baum, G. D. Demetri. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in patients with advanced GIST [abstract]. Proceedings of the American Society of Clinical Oncology. 2007; 10015.
  125. G. D. Demetri, S. George, J. A. Morgan, A. Wagner, M. T. Quigley, K. Polson, J. Pokela, A. van den Abbeele, J. Adams, D. Grayzel. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial [abstract]. Proceedings of the American Society of Clinical Oncology. 2007; 10024.
  126. Mery, CP; George, S; Raut CP. Secondary sarcomas after radiation in patients with breast cancer [abstract]. Proceedings of the American Society of Clinical Oncology. 2007; 10072.
  127. Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007 May 01; 109(9):1863-9. PMID: 17385194.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  128. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006 Nov 07; 145(9):660-4. PMID: 17088579.
    Citations: 84     Fields:    Translation:HumansCTClinical Trials
  129. Raut CP, Dileo P, Morgan JA, Wagner AJ, Demetri GD, George S, Bertagnolli MM. Long term disease control in patients with desmoid fibromatosis managed with multimodality therapy [abstract]. Connect Tissue Oncology Society. 2006; 50.
  130. George S, Blay JY, Casali PG, Le Censne A, Morgan JA, Tyler AR, Quigley MT, Tassell V, Baum CM, Demetri GD. Continuous daily dosing of sunitinib in patients with advaned gastrointestinal stromal tumor (GIST)[abstract]. Connective Tissue Oncology Society. 2006; 648.
  131. George S, Evans TRJ, Wang D, MacPherson IRJ, LoRusso PM, van den Abbeele A, Brunton VG, Luo R, Voi M, Demetri GD . Phase I study of dasatinib, a SRC and multi-kinase inhibitor, in patients with GIST and other solid tumors [abstract]. Connective Tissue Oncology Society. 2006; 74.
  132. Schuetze S, Chow WA, Blay JY, Demetri GD, George S. AP23573 induced long-term tumor stability in 2 patients with desmoplastic small round cell tumor (DSRCT) [abstract]. Connective Tissue Oncology Society. 2006; 52.
  133. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14; 368(9544):1329-38. PMID: 17046465.
    Citations: 737     Fields:    Translation:Humans
  134. George S and Demetri GD. Gastrointestinal stromal tumors in the era of targeted therapy. Hospital Physician Oncology Board Review Manual. 2006; 8(5):1-11.
  135. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24(15):2325-31. PMID: 16710031.
    Citations: 143     Fields:    Translation:Humans
  136. George S, Desai J, Paul Eder J, Manola J, Ryan DP, Appleman LJ, Demetri GD. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer. 2006 May; 42(7):864-70. PMID: 16503137.
    Citations: 8     Fields:    Translation:Humans
  137. Raut CP, Van DenAbeele A, Ramaiya N, Morgan JA, George S, Tyler AR, Quigley MT, Dollard AM, Bertagnolli MM, Demetri GD. Patterns of PET response after long term sunitinib therapy in patients with imatinib resistant gastrointestinal stromal tumors [abstract]. Proceedings of the American Society of Clinical Oncology. 2006; 9547.
  138. George S, Demetri GD. Soft Tissue Sarcoma. 2006.
  139. George S, Casali PG, Blay J, Le Cesne A, Tyler AR, Quigley MT, Tassell V, Baum C, Demetri GD. Phase II Study of sunitinib administered in a continuous daily dosing regimin in patients with advanced GIST [abstract]. Proceedings of the American Society of Clinical Oncology. 2006; 9532.
  140. Evans TR, Morgan JA, van den Abbeele AD, McPherson IR, George S, Crawford D, Mastrullo JM, Cheng S, Fletcher JA, Demetri GD. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors [abstract]. Proceedings of the American Society of Clinical Oncology. 2005; 3034.
  141. Davis DW, McConkey DJ, Heymach JV, Desai J, George S, Jackson J, Bello CL, Baum C, Shalinsky DR, Demetri GD. Pharmacodynamic Analysis of Target Receptor Tyrosine Kinase Activity and Apoptosis in GIST Tumors Responding to Therapy with SU11248 [abstract]. Proceedings of the American Society of Clinical Oncology. 2005; 3006.
  142. Maki RG, Fletcher JA, MHeinrich MC, Morgan JA, George S, Desai J, Scheu K, Fletcher CD, Baum C, Demetri GD. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)[abstract]. Proceedings of the American Society of Clinical Oncology. 2005; 9011.
  143. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003 Nov; 18(11):937-47. PMID: 14687281.
    Citations: 63     Fields:    Translation:Humans
  144. Lee BH, George S, Kutok JL. Langerhans cell histiocytosis involving the thymus. A case report and review of the literature. Arch Pathol Lab Med. 2003 Jul; 127(7):e294-7. PMID: 12823060.
    Citations: 7     Fields:    Translation:Humans
  145. George S, Hornick JL, Bertagnolli MM, Fletcher CD, Demetri GD. Current management of metastatic gastrointestinal stromal tumor: a case report. Clin Adv Hematol Oncol. 2003 Jan; 1(1):63-4; discussion 65. PMID: 16227963.
    Citations:    Fields:    Translation:Humans
  146. George S, Desai J. Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. Curr Treat Options Oncol. 2002 Dec; 3(6):489-96. PMID: 12392638.
    Citations: 7     Fields:    Translation:Humans
  147. George S, Demetri GD. Soft Tissue Sarcoma. in Straus DJ (ed): Educational Manual in Medical Oncology. 2002; 1-15.
  148. Vance E, George S, Guinan EC, Wheeler C, Antin JH, Ambrosino DM, Molrine DC. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant. 1998 Oct; 22(8):735-41. PMID: 9827969.
    Citations: 9     Fields:    Translation:HumansCells
  149. George S, Schell MJ, Detterbeck FC, Socinski MA. Adjuvant Chemotherapy for Resected Non-Small Cell Carcinoma of the Lung: Why We Still Don't Know. Oncologist. 1998; 3(1):35-44. PMID: 10388082.
    Citations: 3     Fields:    
  150. Molrine DC, Guinan EC, Antin JH, Wheeler C, Parsons SK, Weinstein HJ, McGarigle C, Blanding P, Phillips NR, Ciamarra A, George S, Ambrosino DM. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1149-55. PMID: 8807128.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  151. Molrine DC, Guinan EC, Antin JH, Parsons SK, Weinstein HJ, Wheeler C, McGarigle C, Blanding P, Phillips NR, Kinsella K, Deans K, Ciamarra A, Goorin A, George S, Ambrosino DM. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996 Apr 01; 87(7):3012-8. PMID: 8639924.
    Citations: 15     Fields:    Translation:Humans
  152. Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, Shamberger RC, Phillips NR, Goorin A, Ambrosino DM. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis. 1996 Jan; 173(1):256-8. PMID: 8537671.
    Citations: 24     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  153. Molrine DC, George S, Tarbell N, Mauch P, Diller L, Neuberg D, Shamberger RC, Anderson EL, Phillips NR, Kinsella K, Ambrosino DM. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med. 1995 Dec 01; 123(11):828-34. PMID: 7486464.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
George's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (371)
Explore
_
Co-Authors (104)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.